Skip to content

Can deep phenotyping using retinal images predict response to intravitreal aflibercept therapy in patients with neovascular age-related macular degeneration?

Can deep phenotyping using retinal images predict response to intravitreal aflibercept therapy in patients with neovascular age-related macular degeneration?

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN28276860
Enrollment
3000
Registered
2019-08-27
Start date
2019-12-01
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wet age-related macular degeneration Eye Diseases

Interventions

The OCT and OCTA images taken at baseline and various time points until after the third aflibercept injection for wet AMD will be evaluated by retinal specialists and artificial intelligence to develo

Sponsors

Moorfields Eye Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria for both retrospective and prospective parts: 1. Adults who are = 50 years and = 100 years 2. Treatment naïve neovascular AMD at baseline 3. Media clarity, pupillary dilation and patient cooperation for adequate imaging 4. Ability to give informed consent Inclusion criteria for retrospective part only in addition to the above: 1. Have received 3 loading injections of intravitreal aflibercept therapy at monthly intervals as per standard care 2. Review up to 10 weeks after the 3rd loading dose with or without injection at this visit 3. Had Heidelberg OCT at least at baseline and after the loading phase but ideally 4 Heidelberg OCTs for the 4 visits 4. Heidelberg OCTA images if available for baseline and any visit thereafter (2nd, 3rd or 4th visit) provided there is a baseline OCTA (optional criteria)

Exclusion criteria

Exclusion criteria: 1. Co-existent ocular disease: any other ocular condition that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study 2. Any patient who has opted out of their information being used for research nationally or locally at any site

Design outcomes

Primary

MeasureTime frame
Diagnostic accuracy of artificial intelligence over human graders in assessing the response of loading phase of intravitreal aflibercept injections for wet age-related macular degeneration

Secondary

MeasureTime frame
1. The analyses will be repeated excluding patients who appeared in the training set and the primary validation set 2. Performance of the AI will be evaluated using higher-quality images with no media opacity (eg, cataracts) as noted by professional graders 3. AUC subgroups will be computed stratified by age and sex, smoking or medical history 4. The analysis will be repeated by calculating the AUC, sensitivity, and specificity of the AI and the proportion of concordant and discordant eyes on the external validation datasets, compared with the reference standards

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026